Voyager Therapeutics, Inc.
VYGR
NASDAQ·Healthcare·Biotechnology·Mkt cap $212.1M
$3.51
▲ +3.85%
P/E
-1.94
Mkt Cap
$212.1M
52-Wk Range
$2.94–$5.55
52-Week Range
$2.94 - $5.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 17.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary AAV gene therapy platform with next-generation technology capabilities
- Strategic partnerships with Pfizer, Novartis, and Neurocrine providing development and commercialization support
- Focused pipeline targeting high-prevalence neurological diseases with significant unmet medical needs
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Clinical trial progression of VY-AADC and advancement of preclinical candidates toward IND applications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VYGR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.40 vs -$0.48 consensus (+17.3% surprise). Revenue of $3.2M vs $4.5M expected (-30.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+17.3%
Revenue trend · last 8Q
—
-93%
-67%
-82%
-46%
+144%
-60%
-39%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$24.6M
$6.3M
$6.5M
$5.2M
$13.4M
$15.3M
$2.6M
$3.2M
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
-773.2%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 27, 2026
vs Industry
How VYGR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related